Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12572961 | 0.89 | ALDH1A1 (0.45) | POLBSIGMAR1MAPK1L3MBTL1GAA | |
| SCHEMBL692224 | 0.85 | NPSR1 (0.50) | SIGMAR1MAPK1L3MBTL1BLMKMT2A | |
| SCHEMBL692294 | 0.85 | ALDH1A1 (0.47) | SIGMAR1MAPK1L3MBTL1BLMALDH1A1 | |
| SCHEMBL691773 | 0.85 | ALDH1A1 (0.41) | POLBSIGMAR1MAPK1L3MBTL1GAA | |
| SCHEMBL692074 | 0.84 | POLB (0.44) | POLBSIGMAR1MAPK1L3MBTL1GAA | |
| SCHEMBL12572944 | 0.81 | CA1 (0.43) | SIGMAR1ALDH1A1 | |
| SCHEMBL12572997 | 0.81 | ALDH1A1 (0.51) | POLBSIGMAR1MAPK1L3MBTL1BLM | |
| SCHEMBL25154608 | 0.80 | DRD4 (0.46) | SIGMAR1ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL25154267 | 0.80 | DRD4 (0.46) | SIGMAR1ALDH1A1KDM4EKMT2ALMNA | |
| SCHEMBL7978124 | 0.79 | FFAR1 (0.52) | ALDH1A1KDM4EKMT2AMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE DEUTSCHLAND (DE) | 2018-05-10 | — | — | US | disclosed |
| US-9701679-B2 | Modulators of 5-HT receptors and methods of use thereof | Abb Vie Deutschland GmbH & Co. KG (DE) | 2017-07-11 | — | — | US | disclosed |
| US-20160052929-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | ABBVIE INC. | 2016-02-25 | — | — | US | disclosed |
| US-9133206-B2 | Benzodiazepine and pyridodiazepine derivatives | ABBVIE INC. (US) | 2015-09-15 | — | — | US | disclosed |
| US-20150175611-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-25 | — | — | US | disclosed |
| US-8846663-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20140163014-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | ABBVIE INC. | 2014-06-12 | — | — | US | disclosed |
| US-8673896-B2 | Benzodiazepine and pyridodiazepine derivatives | ABBVIE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBVIE INC. | 2013-11-21 | — | — | US | disclosed |
| US-8546377-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-8518933-B2 | Modulators of 5-HT receptors and methods of use thereof | ABBVIE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110288069-A1 | Benzodiazepine and Pyridodiazepine Derivatives | ABBOTT LABORATORIES (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2011-06-02 | — | — | US | disclosed |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310368-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | POLB 4586/4885SIGMAR1 77/4885MAPK1 2664/4885 |
| US-20110130382-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | POLB 4586/4885SIGMAR1 77/4885MAPK1 2664/4885 |
| US-20110288069-A1 | Benzodiazepine and Pyridodiazepine Derivatives | GABRA3, GABRB3, GABRA1 | POLB 3753/4885SIGMAR1 149/4885MAPK1 2372/4885 |
| US-20180127423-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | POLB 4586/4885SIGMAR1 77/4885MAPK1 2664/4885 |
| US-20160052929-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | GABRA3, GABRB3, GABRA1 | POLB 3753/4885SIGMAR1 149/4885MAPK1 2372/4885 |
| US-20140163014-A1 | BENZODIAZEPINE AND PYRIDODIAZEPINE DERIVATIVES | GABRA3, GABRB3, GABRA1 | POLB 3753/4885SIGMAR1 149/4885MAPK1 2372/4885 |
| US-20100273767-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | POLB 4586/4885SIGMAR1 77/4885MAPK1 2664/4885 |
| US-20150175611-A1 | MODULATORS OF 5-HT RECEPTORS AND METHODS OF USE THEREOF | HTR4, HTR1A, HTR1D | POLB 4586/4885SIGMAR1 77/4885MAPK1 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.